United Therapeutics
UTHR
511 hedge funds and large institutions have $12.3B invested in United Therapeutics in 2022 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 167 increasing their positions, 176 reducing their positions, and 27 closing their positions.
233% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 27
32% more capital invested
Capital invested by funds: $9.35B → $12.3B (+$2.98B)
28% more funds holding in top 10
Funds holding in top 10: 18 → 23 (+5)
16% more call options, than puts
Call options by funds: $50.3M | Put options by funds: $43.5M
11% more funds holding
Funds holding: 459 → 511 (+52)
0.79% less ownership
Funds ownership: 98.12% → 97.33% (-0.79%)
5% less repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 176
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$306M |
| 2 |
FAM
Fred Alger Management
New York
|
+$46.3M |
| 3 |
BlackRock
New York
|
+$46.2M |
| 4 |
Morgan Stanley
New York
|
+$33.5M |
| 5 |
D.E. Shaw & Co
New York
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$98.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$73.1M |
| 3 |
Renaissance Technologies
New York
|
-$51.9M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$46.6M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
-$38.8M |
UTHR Hedge Fund Activity: Q4 2022 in Review
511 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2022, worth a combined $12.3B — up 32% from $9.35B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new UTHR positions and 27 closed out — a net gain of 63 holders — while 167 added to existing stakes and 176 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $306M. The largest seller was Fidelity Investments, cutting an estimated $98.6M.
- 511 institutional investors held United Therapeutics (UTHR) as of Q4 2022, up from 459 in Q3 2022.
- Funds reported $12.3B of United Therapeutics stock for Q4 2022, up 32% quarter-over-quarter.
- 90 funds opened new United Therapeutics positions in Q4 2022 and 27 closed out, a net change of +63 holders.
- The largest United Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $306M added.
- The largest United Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $98.6M sold.
Based on aggregated 13F filings for Q4 2022.